Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05675527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PRP for Glenohumeral Osteoarthritis

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Sep 1, 2026 → Jun 1, 2028
See other at-risk trials from Hospital for Special Surgery, New York

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2026 to Jun 1, 2028
    • Study completion pushed from Sep 1, 2026 to Jun 1, 2029
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 5 of 6 entries
  2. Primary and study completion dates: Sep 1, 2025 to Sep 1, 2026v6
  3. Primary completion date: Sep 1, 2024 to Sep 1, 2025
    • Study completion date: Feb 1, 2025 to Sep 1, 2025
    v5
  4. Primary completion date: May 1, 2024 to Sep 1, 2024v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 20, 2023 to May 2, 2023
    • Site details revised
    v3
  6. Start date: Jan 30, 2023 to Mar 20, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.
Trial Details
NCT Number NCT05675527
Lead Sponsor Hospital for Special Surgery, New York
Conditions
(from sponsor)		 Shoulder Osteoarthritis
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov